Topical cosmetic treatment of skin and scalp and corresponding active ingredient based on an extract of <i>Apium graveolens</i>

Abstract

The invention provides the use of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide for the topical cosmetic treatment of the skin and of the scalp, in particular an anti-dandruff treatment. According to the invention, a CO.sub.2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.

Claims

1. A method for stimulating collagen production in dermal fibroblasts for treating skin in need thereof, comprising contacting the fibroblasts with an effective amount of a mixture of alkyl-phthalides or a plant extract comprising a mixture of alkyl-phthalides, wherein the mixture of alkyl-phthalides consists of sedanenolide, sedanolide and 3-n-butylphthalide, where sedanenolide is a major compound in the mixture, and wherein the extract comprises at least 50% of the mixture of alkyl-phthalides.

2. The method according to claim 1, wherein the plant extract is an extract of seeds of Apium graveolens.

3. The method according to claim 2, wherein the extract is prepared by a CO.sub.2 supercritical extraction.

4. The method according to claim 3, wherein the extract is prepared by a CO.sub.2 supercritical extraction of ground seeds between 75 and 300 bars pressure and between 30 and 80° C.

5. The method according to claim 1, wherein the alkyl-phthalide mixture is at least 50% by weight of sedanenolide based on the total weight of the alkyl-phthalides.

6. The method according to claim 1, wherein the treatment is an anti-wrinkle treatment.

7. The method according to claim 1, wherein the treatment is for improving mechanical properties of the skin.

8. The method according to claim 1, wherein the alkyl-phthalide mixture or the plant extract is diluted in a physiologically acceptable medium.

9. The method according to claim 1, wherein the alkyl-phthalide mixture or the plant extract is in a form bound to or incorporated in or absorbed in or adsorbed on clothing that comes into contact with the skin.

10. The method according to claim 8, wherein the physiologically acceptable medium is a hydrophobic matrix or a combination of a hydrophilic matrix with a surfactant.

11. The method according to claim 8, wherein the physiologically acceptable medium comprises water, a hydro-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a micro-emulsion, an aqueous gel, an anhydrous gel, a serum, a dispersion of vesicles or a powder.

12. The method according to claim 1, wherein the alkyl-phthalide mixture is 45-90% by weight of sedanenolide based on the total weight of the alkyl-phthalides.

Description

DETAILED DESCRIPTION

(1) The present invention will be better understood and other advantages will appear from the following detailed description of preparation examples and in vitro and in vivo tests.

(2) Preparation of Compositions According to the Invention

(3) A cosmetic composition, especially topical, comprises at least one alkyl-phthalide or a plant extract comprising in majority said at least one alkyl-phthalide in a physiologically acceptable medium. According to the excipient and the alkyl-phthalide dosage, this composition will be a concentrated active ingredient or a final composition less concentrated directly for the end user.

(4) “Physiologically acceptable medium” means according to the present invention, without limitation, an aqueous or hydro-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a micro-emulsion, an aqueous gel, an anhydrous gel, a serum, a dispersion of vesicles, or a powder.

(5) “Physiologically acceptable” means that the compositions are suitable for topical or transdermal use, in contact with mucous membranes, appendages (nails, hairs), scalp and skin of mammals, particularly human, compositions which may be ingested, or injected into the skin, without risk of toxicity, incompatibility, instability, allergic response, and others.

(6) This “physiologically acceptable medium” forms what is commonly called the excipient of the composition. The alkyl-phthalide(s) or plant extract comprising such may be combined with other active ingredients at effective concentrations that can act synergistically or additionally for reinforcing and achieving the desired effects described for the invention, such as the following agents: UVA and/or UVB radiation filtering agents, hydrating, moisturizing, humectant, calming, dermo-relaxing, slimming, restructuring, firming, replumping, lifting, antidandruff, smoothing, acting on blood microcirculation, inflammation, free radicals, anti-aging, anti-fine lines and wrinkles, lightening, acting on complexion, anti-glycation, anti-carbonylation, pro-pigmenting, acting on stratum corneum, on dermal-epidermal junction, on HSP protein production, on firmness, elasticity and tone of skin, on hair growth or anti-regrowth (including eyelashes and eyebrows), on eye contours (dark circles and under eye bags), peptides, vitamins, etc.

(7) For a scalp treatment in addition to or reinforcement of activity is preferably used: An anti-dandruff active acting as antifungal: such as zinc pyrithione, ketoconazole, climbazole, piroctone olamine or selenium disulphide; A moisturizing agent such as DuraQuench™ (Croda); An active rebalancing the skin microflora as HAIRSPA™ (Sederma); A calming active as PACIFEEL™ (Sederma); and/or An antibacterial, moisturizing and anti-stinging active as OSMOCIDE™ (Sederma); and/or A detoxification and skin reinforcement against air pollutants active as CITYSTEM™ (Sederma); and/or A cosmetic active to prevent hair loss and stimulate their growth as CAPIGENE′, CAPILECTINE™, PROCAPIL™ (Sederma); or to reinforce the structure of damaged hair as CERAMIDE A2™, HELIOGENOL™ (Sederma); or to smooth the hair as FRUIT BIO™ (Sederma).

(8) The treatment of the invention may be applied to all body parts, and more specifically according to the preconized indication to the face, body, neckline or scalp, in whatever form or carrier known to those skilled in the art, in particular in the form of solution, dispersion, emulsion, paste, or powder, individually or as a premix or in vehicles individually or as a premix in vectors such as macro-, micro- or nano-capsules, macro-, micro- or, nano-spheres, liposomes, oleosomes or chylomicrons, macro-, micro-, or nanoparticles or macro-, micro- or nano-sponges, micro- or nano-emulsions or adsorbed on organic polymer powders, talcs, bentonites, spores or exines, and other inorganic or organic supports.

(9) In cosmetics in particular, applications can be offered in skincare ranges for the face, body and scalp.

(10) In general, the alkyl-phthalide(s) or plant extract(s) according to the invention may be used in any form, in a form bound to or incorporated in or absorbed in or adsorbed on macro-, micro-, and nanoparticles, or macro-, micro-, and nano-capsules, for the treatment of textiles, natural or synthetic fibres, wools, and any materials that may be used for clothing or underwear for day or night intended to come into contact with the skin, handkerchiefs or cloths, to exert their cosmetic effect via this skin/textile contact and to allow continuous topical delivery.

(11) The CTFA («International Cosmetic Ingredient Dictionary & Handbook» (16th Ed. 2016) published by «the Personal Care Products council», ex—«the Cosmetic, Toiletry, and Fragrance Association, Inc.», Washington, D.C.), describes a non-limited wide variety of cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use as additional ingredients in the compositions according to the present invention.

(12) Further additional skin care actives that are particularly useful can be found in the commercial literature of Sederma.

(13) The following commercial actives can also be mentioned, as examples: betaine, glycerol, Actimoist Bio 2™ (Active organics), AquaCacteen™ (Mibelle AG Cosmetics), Aquaphyline™ (Silab), AquaregulK™ (Solabia), Carciline™ (Greentech), Codiavelane™ (Biotech Marine), Dermaflux™ (Arch Chemicals, Inc), Hydra'Flow™ (Sochibo), Hydromoist L™ (Symrise), RenovHyal™ (Soliance), Seamoss™ (Biotech Marine), Argireline™ (commercial name for the acetyl hexapeptide-3 of Lipotec), spilanthol or an extract of Acmella oleracea known under the commercial name Gatuline Expression™, an extract of Boswellia serrata known under the commercial name Boswellin™, Deepaline PVB™ (Seppic), Syn-AKE™ (Pentapharm), Ameliox™, Bioxilift™ (Silab), PhytoCellTec™ Argan (Mibelle), Papilactyl D™ (Silab), Preventhelia™ (Lipotec), and from Sederma: Subliskin™, Venuceane™, Moist 24™, Vegesome Moist 24™, Essenskin™, Juvinity™, Revidrat™, Resistem™, Chronodyn™, Kombuchka™, Chromocare™, Calmosensine™, Glycokin factor S™, Biobustyl™, Idealift™, Ceramide 2™, Ceramide A2™ et Ceramide HO3™, Legance™, Intenslim™, Prodizia™, Beautifeye™, Pacifeel™, NG-shea butter unsaponifiables (natural grade), Zingerslim™, Meiritage™, Senestem™, Sebuless™, Majestem™ Rubistem™, Citystem™, or mixture thereof.

(14) Among other plant extracts which can be combined with the alkyl phthalide(s) or plant extract(s) of the invention, there may more particularly be mentioned extracts of Ivy, in particular English Ivy (Hedera helix), of Bupleurum chinensis, of Bupleurum falcatum, of arnica (Arnica montana L), of rosemary (Rosmarinus officinalis N), of marigold (Calendula officinalis), of sage (Salvia officinalis L), of ginseng (Panax ginseng), of Ginko biloba, of St.-John's-Wort (Hyperycum perforatum), of butcher's-broom (Ruscus aculeatus L), of European meadowsweet (Filipendula ulmaria L), of big-flowered Jarva tea (Orthosiphon stamincus benth), of artichoke (Cynara scolymus), of algae (Fucus vesiculosus), of birch (Betula alba), of green tea, of Cola nuts (Cola nipida), of horse-chestnut, of bamboo, of Centella asiatica, of heather, of fucus, of willow, of mouse-ear, of escine, of cangzhu, of Chrysanthellum indicum, of the plants of the Armeniacea genus, Atractylodis platicodon, Sinnomenum, Pharbitidis, Flemingia, of Coleus such as C. Forskohlii, C. blumei, C. esquirolii, C. scutellaroides, C. xanthantus and C. Barbatus, such as the extract of root of Coleus barbatus, extracts of Ballote, of Guioa, of Davallia, of Terminalia, of Barringtonia, of Trema, of antirobia, cecropia, argania, dioscoreae such as Dioscorea opposita or Mexican, extracts of Ammi visnaga, of Siegesbeckia, in particular Siegesbeckia orientalis, vegetable extracts of the family of Ericaceae, in particular bilberry extracts (Vaccinium angustifollium) or Arctostaphylos uva ursi, aloe vera, plant containing sterols (e.g., phytosterol), Manjistha (extracted from plants of the genus Rubia, particularly Rubia cordifolia), and Guggal (extracted from plants of the genus Commiphora, particularly Commiphora mukul), kola extract, chamomile, red clover extract, Piper methysticum extract (Kava Kava™ from Sederma), Bacopa monieri extract (Bacocalmine™ from Sederma) and sea whip extract, extracts of Glycyrrhiza glabra, of mulberry, of melaleuca (tea tree), of Larrea divaricata, of Rabdosia rubescens, of Euglena gracilis, of Fibraurea recisa Hirudinea, of Chaparral sorghum, of sun flower extract, of Enantia chlorantha, of Mitracarpe of Spermacocea genus, of Buchu barosma, of Lawsonia inermis L., of Adiantium capillus-veneris L., of Chelidonium majus, of Luffa cylindrica, of Japanese Mandarin (Citrus reticulata Blanco var. unshiu), of Camelia sinensis, of Imperata cylindrica, of Glaucium flavum, of Cupressus sempervirens, of Polygonatum multiflorum, of loveyly hemsleya, of Sambucus nigra, of Phaseolus lunatus, of Centaurium, of Macrocystis pyrifera, of Turnera diffusa, of Anemarrhena asphodeloides, of Portulaca pilosa, of Humulus lupulus, of Coffea arabica, of Ilex paraguariensis, or of Globularia cordifolia, of Albizzia julibrissin, of Oxydendron arboretum, of Zingimber zerumbet smith, of Astragalus membranaceus, of Atractylodes macrocephalae, of Plantago lanceolata, of Leontopodium alpinum, of Mirabilis jalapa, of Marrubium vulgare, or of orchids.

(15) The compositions of the present invention may include one or more peptides, including, without limitation, di-, tri-, tetra-, penta- and hexapeptides and their derivatives. According to a particular embodiment, the concentration of the additional peptide, in the composition, ranges from 1×10.sup.−7% and 20%, preferably from 1×10.sup.−6% and 10%, preferably between 1×10.sup.−5% and 5% by weight.

(16) According to the present invention, the term “peptide” refers to peptides containing 10 amino acids or less, their derivatives, isomers and complexes with other species such as a metal ion (e.g. copper, zinc, manganese, magnesium, and others). The term “peptides” refers to both natural peptides and synthetic peptides. It also refers to compositions that contain peptides and which are found in nature, and/or are commercially available.

(17) Suitable dipeptides for use herein include but are not limited to Carnosine (βAH), YR, VW, NF, DF, KT, KC, CK, KP, KK, TT, PA, PM or PP.

(18) Suitable tripeptides for use herein include, but are not limited to RKR, HGG, GKH, GGH, GHG, KFK, KAvaK, KβAK, KAbuK, KAcaK, KPK, KMOK, KMO.sub.2K (MO.sub.2 being a di-oxygenated sulfoxide methionine), KVK, PPL, PPR, SPR, QPA, LPA or SPA.

(19) Suitable tetrapeptides for use herein include but are not limited to RSRK (SEQ ID NO: 1), GQPR (SEQ ID NO: 2), KTFK (SEQ ID NO: 3), KTAK (SEQ ID NO: 4), KAYK (SEQ ID NO: 5) or KFYK (SEQ ID NO: 6).

(20) Suitable pentapeptides include, but are not limited to KTTKS (SEQ ID NO: 7). Suitable hexapeptides include but are not limited to GKTTKS (SEQ ID NO: 8) and VGVAPG (SEQ ID NO: 9).

(21) Other suitable peptides for use herein include, but are not limited to: lipophilic derivatives of peptides, preferably palmitoyl (Pal) derivatives, and metal complexes as aforementioned (e.g. copper complex of the tripeptide HGG). Preferred dipeptide include for example N-Palmitoyl-β-Ala-His, N-Acetyl-Tyr-Arg-hexadecylester (Calmosensine™, Idealift™ from Sederma), Pal-RT or Pal-KT (Sederma). Preferred tripeptide derivatives include for example Pal-GKH and Pal-GHK (from Sederma), the copper derivative of HGG (Lamin™ from Sigma), Lipospondin (N-Elaidoyl-KFK) and its analogs of conservative substitution, N-Acetyl-RKR-NH.sub.2 (Peptide CK+), N-Biot-GHK (from Sederma), Pal-KAvaK, Pal-KβAlaK, Pal-KAbuK, Pal-KAcaK, or Pal-KMO.sub.2K (Matrixyl® synthe'6® from Sederma), PalKVK (Syn-Coll™ of DSM), and derivatives thereof.

(22) Here can also be cited the anti-aging tripeptides of general formula X-Pro*-Pro*-Xaa-Y disclosed in WO2015181688 with Xaa selected from Leu, Arg, Lys, Ala, Ser, and Asp; at the N terminal end, X selected from H, —CO—R.sub.1 and —SO.sub.2—R.sub.1 and at the C terminal end Y selected from OH, OR.sub.1, NH.sub.2, NHR.sub.1 or NR.sub.1R.sub.2; R.sub.1 and R.sub.2 being, independently from each other, selected from an alkyl, aryl, aralkyl, alkylaryl, alkoxy et aryloxy group, that can be linear, branched, cyclic polycyclic, saturated, unsaturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, said group having or not an O, S and/or N heteroatom in its skeleton and Pro* corresponding to a Proline, analog or derivative thereof; comprising for example Myr-PPL-OH and Myr-PPR-OH.

(23) Here can further be cited also the propigmenting and/or pro-mec dipeptides and tripeptides of general formula X-(Xaa.sub.1)n-Pro*-Xaa.sub.2-Y disclosed in WO2014/080376, with n=0, 1 or 2, Xaa.sub.1 an hydrophobic aminoacid selected from Ala, Val, Met, Leu, Iso, Phe, Pro, and analogs and derivatives thereof; or a polar aminoacid selected from Ser, Thr, Tyr, Asp, Glu and analogs and derivatives thereof; and when n=2 the two aminoacids Xaa.sub.1 being the same or different; Xaa.sub.2 being an hydrophobic aminoacid selected from Ala, Val, Met, Leu, Iso, Phe, and analogs and derivatives thereof, or a basic aminoacid selected from Arg, Lys, His, and analogs and derivatives thereof; at the N terminal end X being selected from H, —CO—R.sub.1 and —SO.sub.2—R.sub.1; at the C terminal end Y being selected from OH, OR.sub.1, NH.sub.2, NHR.sub.1 or NR.sub.1R.sub.2; R.sub.1 and R.sub.2 being, independently from each other, selected from an alkyl, aryl, aralkyl, alkylaryl, alkoxy et aryloxy group, that can be linear, branched, cyclic polycyclic, saturated, unsaturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, said group having or not an O, S and/or N heteroatom in its skeleton and Pro* corresponding to a Proline, analog or derivative thereof; comprising for example the following peptides Pal-SPR-OH, Pal-PPR-OH, Pal-QPA-OH, Pal-LPAOH, Myr-SPA-OH, Pal-PM-OH, Pal-PA-OH and Pal-PP-OH.

(24) Suitable tetrapeptide derivatives for use according to the present invention include, but are not limited to, Pal-GQPR (SEQ ID NO: 10) (from Sederma) and Pal-KTFK (SEQ ID NO: 11) or Ela-KTFK (SEQ ID NO: 12), Ela-KTAK (SEQ ID NO: 13), Ela-KAYK (SEQ ID NO: 14) or Ela-KFYK (SEQ ID NO: 15). Suitable pentapeptide derivatives for use herein include, but are not limited to, Pal-KTTKS (SEQ ID NO: 16) (available as Matrixyl® from Sederma), Pal-YGGFXaa (SEQ ID NO: 17) with Xaa being Leu or Pro, or mixtures thereof. Suitable hexapeptide derivatives for use herein include, but are not limited to, Pal-VGVAPG (SEQ ID NO: 18), Pal-GKTTKS (SEQ ID NO: 19), Pal-HLDIIXaa with Xaa being Trp, Phe, Tyr, Tic, 7-hydroxy-Tic ou Tpi (SEQ ID NO: 20) and derivatives thereof. The mixture of Pal-GHK and Pal-GQPR (SEQ ID NO: 10) (Matrixyl® 3000, Sederma) can also be mentioned.

(25) The preferred compositions commercially available containing a tripeptide or a derivative include Biopeptide-CL™, Maxilip™, Biobustyl™, Procapil™ and Matrixyl® synthe'6® of Sederma. The compositions commercially available preferred sources of tetrapeptides include Rigin™, Eyeliss™ Matrixyl® Reloaded and Matrixyl 3000® which contain between 50 and 500 ppm of Pal-GQPR (SEQ ID NO: 10) and an excipient, proposed by Sederma.

(26) The following marketed peptides can be mentioned as well as additional active ingredients: Vialox™ (INCI name=Pentapeptide-3 (synthetic peptide comprising alanine, arginine, isoleucine, glycine and proline)), Syn-ake™ (β-Ala-Pro-Dab-NH-Bzl) or Syn-Coll™ (Pal-Lys-Val-Lys-OH) marketed by Pentapharm; Argireline™ (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH.sub.2 (INCI name=Acetyl hexapeptide-3) (SEQ ID NO: 21), Leuphasyl™ (Tyr-D-Ala-Gly-Phe-Leu) (SEQ ID NO: 22), Aldenine™ (Gly-His-Lys), Trylagen™ (INCI name=Pseudoalteromonas Ferment Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline (reaction product of Citrulline and Tripeptide-10 (synthetic peptide constituted of aspartic acid, isoleucine and lysine)), Tripeptide-1), Eyeseryl™ (Ac-β-Ala-His-Ser-His)(SEQ ID NO: 23), Serilesine™ (Ser-Ile-Lys-Val-Ala-Val) (SEQ ID NO 24) or Decorinyl™ (INCI name: Tripeptide-10 Citrulline=reaction product of Citrulline and Tripeptide-10 (synthetic peptide constituted of aspartic acid, isoleucine and lysine) marketed by Lipotec; Collaxyl™ (Gly-Pro-Gln-Gly-Pro-Gln (SEQ ID NO 25)) or Quintescine™ (Cys-Gly) marketed by Vincience; Cytokinol™ LS (casein hydrolysate) marketed by Les Laboratoires Serobiologiques/Cognis; Kollaren™ (Gly-His-Lys), IP2000™ (Pal-Val-Tyr-Val) or Meliprene™ (INCI name=Monofluoroheptapeptide-1: reaction product of acetic acid and a synthetic peptide comprising arginine, glycine, glutamic acid, histidine, norleucine, p-fluorophenylalanine and tryptophan) marketed by l′Institut Européen de Biologie Cellulaire; Neutrazen™ (Pal-His-D-Phe-Arg-NH.sub.2) marketed by Innovations; or BONT-L-Peptide™ (INCI name=Palmitoyl Hexapeptide-19: reaction product of palmitic acid and Hexapeptide-19 (synthetic peptide constituted of asparagine, aspartic acid, lysine and methionine), Timp-Peptide™ (INCI name=Acetyl Hexapeptide-20: reaction product obtained by acetylation of Hexapeptide-20 (synthetic peptide constituted of alanine, glycine, lysine, valine and proline) or ECM Moduline™ (INCI name=Palmitoyl Tripeptide-28: reaction product of palmitic acid and Tripeptide-28 (synthetic peptide constituted of arginine, lysine and phenylalanine) marketed by Infinitec Activos.

(27) More specifically, according to the invention the alkyl-phthalide(s) or plant extract comprising such may be combined with at least one of compounds selected from compounds of the vitamin B3, compounds such as niacinamide or tocopherol, retinoid compounds such as retinol, hexamidine, α-lipoic acid, resveratrol or DHEA, hyaluronic acid, peptides, in particular N-acetyl-Tyr-Arg-O-hexadecyl ester, Pal-VGVAPG (SEQ ID NO: 18), Pal-KTTKS (SEQ ID NO: 16), Pal-GHK, Pal-KMO.sub.2K and Pal-GQPR (SEQ ID NO: 10), which are widely used active ingredients in topical cosmetic or dermopharmaceutical compositions.

(28) The present invention also provides a method of cosmetic or dermatological topical treatment for improving the appearance and condition of the skin and scalp, comprising the topical application to the skin of a subject in need thereof an effective amount of at least one alkyl-phthalide or a plant extract comprising in majority said alkyl-phthalide or a composition comprising them, in a physiologically acceptable excipient.

(29) “Topical treatment” or “topical use” means according to the invention, an application that is intended to act where it is applied: skin and/or scalp.

(30) A composition according to the invention may be applied locally to targeted areas, for example using a cannula type of applicator suitable for the scalp.

(31) The “effective” amount depends on various factors, such as the age, the condition of the patient, the seriousness of the disorder or pathology, the administration mode, etc. An effective amount means a non-toxic amount enough to achieve the desired effect.

(32) All percentages and ratios used herein are by weight of the total composition and all measurements are made at 25° C. unless it is otherwise specified.

(33) For example, for a cosmetic treatment of the face, the European Cosmetics Directive has set a standard amount for applying a cream of 2.72 mg/cm.sup.2/day/person and for a body lotion of 0.5 mg/cm.sup.2/day/person. For example, for a scalp hair treatment, a dose of total phthalides from 0.5 to 2 mg is recommended to apply per week for at least 1 week, preferably at least 3 weeks. For example according to a treatment of at least 3 times per week, applying a dose of 10 grams of shampoo, and then 10 grams of a non-rinsed after-shampoo lotion (“Leave-on”) with respectively 2% (shampoo) and 3% (“Leave-on”) of the active ingredient containing the extract according to the invention (according to formulas 1.1 and 1.2 of the § D Galenics data below).

(34) According to other specific features, the cosmetic treatment method according to the invention can be combined with one or more other treatment methods targeting the skin such as lumino-therapy, heat or aromatherapy treatments.

(35) According to the invention, devices with several compartments or kits may be proposed to apply the method described above which may include for example and non-restrictively, a first compartment containing a composition comprising at least one alkyl-phthalide or a plant extract comprising it as the major compound according to the invention, and in a second compartment another active ingredient and/or excipient, the compositions contained in the said first and second compartments in this case being considered to be a combination composition for simultaneous, separate or stepwise use in time, particularly in one of the treatment methods recited above.

(36) The treatment method according to the invention is more particularly suitable for a cosmetic treatment of the scalp, and in particular of dandruff states, oily skins (treatment of the gloss and/or dilated pores) of lines and wrinkles and loss of mechanical properties of the skin (loss of firmness in particular).

(37) A) Example of Preparation of an Apium graveolens Seeds Extract that can be Used in the Context of the Invention

(38) The Apium graveolens seeds are ground to a particle size of powder around 800 μm. This powder is then extracted with supercritical CO.sub.2 under 90 bars pressure and at 40° C. The residual water that may be present in the final extract is then removed if necessary (for example by decantation, vacuum evaporation, lyophilization). The extraction yield is around 2.5%. The extract is in the form of an oily liquid, clear to slightly opalescent, colorless to pale yellow.

(39) The resulting extract is passed on Ultra High Performance Liquid Chromatography (UHPLC) on a C18 column with as mobile phase a water/acetonitrile gradient, to dose the various phthalides.

(40) This analysis confirms the presence of 71% of total phthalides in the extract comprising the 3-alkyl phthalides: 10% of 3-n-butylphthalide, 30% of sedanolide and 60% of sedanenolide by weight relative to the total phthalides. The extract can be used pure or diluted.

(41) B) Formulation of an Active Ingredient that can be Used in the Context of the Invention

(42) The active ingredient is a composition comprising the extract of Apium graveolens seeds obtained according to A) above dissolved in a matrix forming a physiologically acceptable medium. This active ingredient is particularly intended for the cosmetics industry for the preparation of cosmetics, creams, gels, etc. (See galenic examples at point D) below).

(43) An extract obtained according to A) above can be diluted in any physiologically acceptable fatty excipient to reach at the end a concentration of 500 ppm of alkyl-phthalides. Esterified oil is preferably used of Caprylic/Capric Triglyceride type for this dilution.

(44) For example, and for the description of the in vivo tests and the galenic of point D) below, it is this dilution that has been preferably used. This constitutes the active ingredient that will used itself preferably at between 1 and 5% in a cosmetic composition that can be applied on the skin.

(45) C) In Vitro Test Results

(46) In vitro tests were carried out from a crude extract of seed oil of Apium graveolens manufactured according to the production method described in A) above. In general, 8, 16 and 24 ppm of this extract, respectively corresponding to 5, 10 and 15 ppm of total phthalides, were tested. These amounts correspond themselves to a dosage of application to the skin or scalp of 1%, 2% and 3% of the above active ingredient of point B).

(47) 1. Reducing the Proliferation of Germs Involved in the Formation of Dandruff

(48) a) Action on the Production of an Antimicrobial Natural Peptide (hBD2)

(49) To control the perturbation of its microbial flora, scalp produces antimicrobial natural peptides (PAM) to reduce the proliferation of germs (bacteria, yeast) and their harmfulness. PAM therefore protects the scalp. One of them, the beta-defensin 2 peptide (hBD2) is produced by skin cells and acts by perforating the cell walls of bacteria or yeast.

(50) Principle: Human keratinocytes were grown to mid-confluence for 4 days and receive the product according to the invention in their culture medium, the medium being changed regularly. At the end of the contact, the cells were lysed and the levels of hBD2 are assessed by ELISA. The number of cells is estimated in parallel with a DNA dye for quantifying cells and normalize the data.

(51) TABLE-US-00001 TABLE 1 Modulation of the production of the antimicrobial peptide hBD2 in the keratinocytes in contact with the extract according to the invention for 4 days (n = 3). hBD2; pg/mL/10.sup.6 cell. Variation (%) Control 205 +/− 55 Reference Extract  8 ppm 317 +/− 36  +55%; p < 0.05 according to 16 ppm 385 +/− 35  +88%; p < 0.01 the invention 24 ppm 447 +/− 36 +118%; p < 0.01 No cytotoxic effect noted.

(52) The results show that the extract according to the invention can increase significantly and dose-dependently the production of the antimicrobial peptide hBD2 and thus can inhibit the proliferation of microorganisms involved in dandruff.

(53) b) Action on the Production of a Microbial Receptor (TLR9)

(54) Epithelial cells have at their external surface or on the surface of their endosomes receptor called Toll-Like (or TLR). These structures play a crucial role in innate immunity of the skin. They aim indeed to capture the bacteria, yeast and viruses and trigger an immune response. But too abundant, they promote inflammation. Besides TLR2 and 4, well known and extracellular, TLR-9 is found especially in keratinocytes and is involved in the recognition of several yeast including Malassezia furfur and Malassezia globasa, responsible for the formation of dandruff

(55) Principle: Skin explants (5 mm diameter) from 4 female donors (mean 69 years (45-90 years)) are brought into contact for 3 days, in their culture medium, with a Malassezia yeast suspension. After removal of the yeast suspension, the skins received every day, for 3 days, an after-shampoo solution not rinsed (“Leave-on”; formula 1.2 of below § D Galenics) containing an extract of Apium graveolens according the invention (corresponding to a dose of 15 ppm of total phthalides), or the placebo. After rinsing, the skins are cut and a TLR-9 marking is performed on these sections.

(56) TABLE-US-00002 TABLE 2 Modulation of the expression of TLR9 in skin explants after contact with Malassezia, effect of the extract according to the invention and its placebo (n = 4; 12 photos/donor). Variation Variation TLR-9; AFU* (%) (%) Control 23.0 +/− 5.5 Reference 1 — Malassezia then 25.9 +/− 6.7 +12.6%, Reference 2 << Leave-on >> placebo p < 0.05 Malassezia then 21.8 +/− 4.3 — −16%; << Leave-on >> according p < 0.01 to the invention *AFU: Arbitrary Fluorescence Unit.

(57) Contact with Malassezia yeast increased TLR-9 labeling in the explants. Use of the extract according to the invention enabled to control the increase (−16%) significantly compared to placebo (p<0.01).

(58) Both tests show that the extract according to the invention disadvantages the metabolism of yeast responsible for dandruff formation and thus allows purifying and embellishing the scalp.

(59) 2. Reducing the Sebum Production

(60) Oily skin is associated with a too abundant sebum production by the cells called sebocytes. Too much sebum often leads to modify the properties of the skin and scalp.

(61) Sebum “glues” dead skin, traps bacteria and yeast (like Malassezia furfur at the scalp level, causing dandruff) that feed on and proliferate.

(62) Decrease of Lipid Synthesis in the Sebocyte

(63) Principle: Human sebocytes (26 years female, face) were seeded in their growth medium. At confluence, the cells were putted in contact with the extract according to the invention for 48 hours. After removing media, monolayers were incubated with Nile Red marker of intracellular lipids which estimates the amount of lipids in the cells. The estimate of the viability is performed in parallel on the same layers using a fluorescent dye.

(64) TABLE-US-00003 TABLE 3 Modulation of lipid synthesis in sebocytes in the presence or not of the extract according to the invention (n = 3). Lipids; Variation AFU*/10.sup.6 cell. (%) Control 282975 +/− 11632 Reference Extract  8 ppm 255691 +/− 7322  −10%; p < 0.05 according to 16 ppm 198976 +/− 9368  −30%; p < 0.01 the invention 24 ppm 169424 +/− 433  −40%; p < 0.01 *AFU: Arbitrary Fluorescence Unit; no cytotoxic effect noted. Linoleic acid: +66% of lipids

(65) These results show that exposure of sebocytes to the extract according to the invention can significantly reduce and dose-dependently the amount of lipids in the cells that produce the sebum.

(66) The extract according to the invention can be used to treat skin disorders associated with oily skin or with an oily tendency, like shiny or glossy aspect, size and number of pores.

(67) The scalp can be “cleaned up” with less sebum, ground for bacteria and yeasts, and traps for dandruff

(68) 3. Reinforcement of the Skin Barrier and its Functions

(69) The scalp of people with a dandruff state presents cells that are poorly differentiated, little cornified and less cohesive, presents less prevalence of ceramide type lipids, an increased transepidermal water loss and a disruption of hydration. Improvement of the skin barrier upstream also helps prevent a dandruff state.

(70) a) Preliminary Study on DNA-Array

(71) A DNA-Array study on normal human keratinocytes in contact with the extract of the invention showed the induction of several genes associated with the reinforcing of the skin barrier compared to the control. 1) The expression of genes coding for loricrin, involucrin and two forms of filaggrin (filaggrin and filaggrin-2) is increased in contact with the extract according to the invention. These proteins are well known to be major players in the cornification and hydration of the stratum corneum. 2) In parallel, the increase of the expression of the cornuline gene is also observed in contact with the extract according to the invention. This protein, found on the scalp, is a marker of the terminal differentiation of the epidermis. Its importance in the homeostasis of the stratum is underlined by the fact that it is reduced in eczema, a chronic inflammatory disease skin. 3) Finally, the extract according to the invention increases the production of SPINK5 and, in parallel, moderates the gene expression of KLK6 and 13. Desquamation results from a balance between KLK (Kallikrein-related peptidase), which break the ties of the corneocyte between them and SPINK5 (Serine Protease Inhibitor Kazal-type 5) that moderates their activity. Loss of function of SPINK5 causes hyper-desquamation of immature cells and a loss of homeostasis of the stratum corneum.

(72) b) Improvement of the Quality of Keratinocyte Differentiation

(73) Normal human keratinocytes almost at confluence are contacted with the extract according to the invention (8 ppm) in an appropriate culture medium in order to study their differentiation in microscope by following the aspect of the layers. At 3 days, the aspect of differentiation is assessed visually. With the extract according to the invention a marked acceleration of the differentiation is observed with stimulation of the formation of typical structures of the top layers of the epidermis (presence of branched structures characteristic of the protein-lipid rigid matrix and in multilayers of the horny envelope; refractive network).

(74) c) Protein Markers of Epidermal Differentiation

(75) Involucrin, loricrin, filaggrin, LCE3B (“Late Cornified Envelope protein 3B”) and SPRR (“small proline-rich region proteins”) are among the proteins responsible for the quality of the barrier function conferred to the stratum corneum.

(76) Principle: the same cell layers as those discussed above in the fresh state in part b) are fixed and immunolabeled to visualize the synthesis of these 5 protein markers of epidermal differentiation. 5 photos are made on each of the 3 replicas. A quantification of the labeling is performed by image analysis. A counter-staining of cell nuclei can estimate the number of cells and thus normalize the data.

(77) Involucrin

(78) TABLE-US-00004 TABLE 4 Modulating the expression of involucrin by keratinocytes in contact with the extract according to the invention (15 photos/case) Involucrin (AFU*/10.sup.6 cell.) Variation Control 7.5 +/− 9.4 Référence Extract  8 ppm 206 +/− 94   ×27; p < 0.01 according to 16 ppm 1134 +/− 291  ×151; p < 0.01 the invention 24 ppm 1014 +/− 74  ×135; p < 0.01 *AFU: Arbitrary Fluorescence Unit; no cytotoxic effect noted.

(79) Loricrin

(80) TABLE-US-00005 TABLE 5 Modulating the expression of loricrin by keratinocytes in contact with the extract according to the invention (15 photos/case) Loricrin (AFU*/10.sup.6 cell.) Variation Control 39 +/− 28 Reference Extract  8 ppm 149 +/− 76   ×3.8; p < 0.01 according to 16 ppm 491 +/− 369 ×12.6; p < 0.01 the invention 24 ppm 1161 +/− 501  ×29.8; p < 0.01 *AFU: Arbitrary Fluorescence Unit; no cytotoxic effect noted.

(81) Filaggrin

(82) TABLE-US-00006 TABLE 6 Modulating the expression of filaggrin by keratinocytes in contact with the extract according to the invention (15 photos/case) Filaggrin (AFU*/10.sup.6 cell.) Variation Control 182 +/− 150 Reference Extract  8 ppm 460 +/− 263 +153%; p < 0.01 according to 16 ppm 613 +/− 182 +237%; p < 0.01 the invention 24 ppm 347 +/− 138  +91%; p < 0.01 *AFU: Arbitrary Fluorescence Unit; no cytotoxic effect noted.

(83) In parallel, the production of the protein SPRR2B (SPRR marker) is increased in the keratinocytes in culture of 103% to 139% (p<0.01) in contact of 16 to 20 ppm of the extract according to the invention compared to the control.

(84) In addition, the LCE3B, induced when it is necessary to repair the skin barrier, show an increased production of +41% to +70% (p<0.01) with 16 to 24 ppm of the extract according to the invention.

(85) All these results are consistent to show the interest of the Apium graveolens seed extract according to the invention in the establishment, reinforcement and restoration of the skin barrier. Protein markers known for the quality of the formation of this barrier: involucrine, loricrin, filaggrins, but also SPRR2B or LCE3B, are all increasing thanks to the extract according to the invention.

(86) d) Epidermal Lipids: Cholesterol, Ceramide 2 and Neutral Free Fatty Acids

(87) The scalp of persons with dandruff is characterized by lower levels of intercellular lipids in the horny layer (including ceramides, cholesterol and neutral lipids). This contributes to the weakening of the skin barrier.

(88) Cholesterol

(89) The DNA-Array study also showed, in the presence of the extract according to the invention, the induction of the CYP51A1 gene, encoding a protein of the cytochrome P450 family, which participates in cholesterol synthesis by catalyzing the removal of the lanosterol 14 alpha-methyl group.

(90) Neutral Lipids

(91) A similar culture to that carried out for proteins (above) is labeled with a specific dye of neutral lipids (cholesterol and derivatives, triglycerides and fatty acid). After photos, an image analysis can estimate the amount of neutral lipids. The amount of cells was estimated using a counterstain of the nuclei.

(92) TABLE-US-00007 TABLE 7 Modulation of the production of neutral lipids by keratinocytes in contact with the extract according to the invention (15 photos/case) Lipids (AFU*/10.sup.6 cell.) Variation Control 22 +/− 11 Reference Extract  8 ppm 132 +/− 85    ×6; p < 0.01 according to 16 ppm 233 +/− 68  ×10.6; p < 0.01 the invention 24 ppm 230 +/− 71  ×10.5; p < 0.01 *AFU: Arbitrary Fluorescence Unit; no cytotoxic effect noted.

(93) Ceramides on Keratinocyte Culture and Explants

(94) A similar culture to that performed above is labeled with an antibody specific of ceramide 2. After taking the photos, image analysis can estimate its amount. The amount of cells was estimated using a counterstain of the nuclei.

(95) Moreover, the same 4 explants as those used for the TLR9 study are immuno-marked to reveal changes in ceramide 2 content. After photos (n=12), an image analysis can quantify them.

(96) TABLE-US-00008 TABLE 8 Modulation of the production of ceramics 2 by keratinocytes and explants in contact with the extract according to the invention (15 photos/case) Keratinocytes Explants Ceramide 2* Variation Ceramide 2* Variation Control/placebo 456 +/− 471 Reference 18.9 +/− 7.2  Reference Extract according 944 +/− 364 +107%; p < 0.01 26.4 +/− 11.2 +40%; p < 0.01 to the invention** *in AFU 10.sup.6 cell.: Arbitrary Fluorescence Unit; no cytotoxic effect noted. **Extract according to the invention: 16 ppm for the keratinocytes; 24 ppm in the << Leave-on >> solution for the explants.

(97) In addition to the increase of expression of an enzyme involved in the formation of cholesterol, the increase in neutral lipids and ceramide 2, components of the skin barrier, is noted. These results thus show that contact with the extract according to the invention strengthens the lipid composant of the skin barrier.

(98) 4. Soothing the Scalp—Reduction of Irritants Signals

(99) a) Effect of the Extract of the Invention on the Production of IL-8

(100) IL-8 is a mediator produced inter alia by keratinocytes in response to the detection of microbial or chemical agents or following UV treatment. The IL-8 guides the immune cells to the origin of the irritation and high levels of IL-8 are found in the squams of people with dandruff. With histamine, it is one of clear markers of dandruff.

(101) Yeast, because of their lipase, excretes irritating lipid byproducts of unsaturated fatty acids type or substrates for the eicosanoid pathway. A model solution of these lipid byproducts (SPL) is prepared and used to assess the soothing properties of the extract according to the invention.

(102) Principle: Normal human keratinocytes brought almost to confluence are contacted 24 h with the growth medium containing or not containing the extract according to the invention. The media are replaced by the same media supplemented or not with the SPL model solution. After 24 hours, the supernatants were assayed for their content of IL-8 and an estimate of the number of cells is made by the MTT method.

(103) TABLE-US-00009 TABLE 9 Modulation of the production of IL-8 by keratinocytes after contact with SPL-Effect of the extract according to the invention (n = 5). Without SPL With SPL IL-8 Variation IL-8 Variation (pg/10.sup.6 cell.) (%) (pg/10.sup.6 cell.) (%) Control 1012 +/− 172  Reference 1 1639 +/− 518  +62%; Reference 2 Extract 16 ppm 597 +/− 374 −41%, p < 0.01 982 +/− 130 −40%; p < 0.01 according to 20 ppm 408 +/− 88  −60%, p < 0.01 796 +/− 103 −51%; p < 0.01 the invention 24 ppm 249 +/− 32  −75%, p < 0.01 569 +/− 100 −65%; p < 0.01 * no cytotoxicity was observed

(104) The SPL increase the production of IL-8 by keratinocytes (+62%; p<0.01), thus modeling what is observed in dandruff states. The extract according to the invention can clearly and significantly reduce the overproduction of 40 to 65% (p<0.01). Moreover, the extract of the invention also reduced markedly and significantly the basal production of IL-8 41 to 75% (p<0.01).

(105) 5. Action on Dermal Extracellular Matrix—Stimulation of Collagen Synthesis

(106) The extracellular matrix is the center piece of maintaining the skin vitality and viscoelastic properties of the dermis. The components of this matrix undergo qualitative and quantitative structural changes over time and under the effect of free radical processes (mainly the sun, pollution and poor living conditions), leading to skin aging and the appearance of fine lines and wrinkles.

(107) Collagen I is a crucial element for the balance of this matrix. Its production decreases with age, and its fibers are degraded by endogenous and exogenous radical processes. UVs also stimulate the synthesis of certain proteolytic enzymes that degrade the proteins of the extracellular matrix. This results in a loss of firmness, elasticity and skin density. So collagen stimulation is a key factor in the cosmetic treatment for beautifying the skin.

(108) Principle: Normal human fibroblasts (NHF) are cultured for 24 h. The cells are contacted or not with the products to be tested or their excipient at various concentrations for 7 days. The synthesis of type I collagen produced by the cells in the form of extracellular matrix is then quantified by immuno-marking on the fixed layers. A count of nuclei labeled with Hoechst is performed in parallel in order to have an estimate of the viability and to weight the data.

(109) TABLE-US-00010 TABLE 10 Stimulating the synthesis of collagen I by fibroblasts, after contact with the extract according to the invention % de variation/ Significance Product Concentration control (Student test) Extract 10 ppm +388% p < 0.01 according to 15 ppm +404% p < 0.01 the invention 20 ppm +472% p < 0.01

(110) D) Galenic

(111) Various cosmetic formulations are described below. Additional active ingredients, coming when appropriate in support and/or in addition to the activity of the active ingredient according to the invention can be added in the correct formulation part according to their hydrophobic or hydrophilic nature. These ingredients can be of any category according to their(s) function(s), site of application (body, face, neck, chest, hands, etc.), the desired end and the targeted consumer.

(112) Active ingredient according to the invention used in the galenic formulations given below: CO.sub.2 supercritic extract of Apium graveolens seeds included in an ester oil of Caprylic/Capric Triglyceride type so as to be at the end at 500 ppm of total alkyl phthalides.

(113) This ingredient is preconized between 0.1 and 10%, preferably between 1 and 5%, more preferably between 2 and 3%.

(114) 1) Scalp Treatment

(115) 1.1 Shampoo

(116) TABLE-US-00011 PRODUCT % INCI NAME Part A H.sub.2O qsp100 Water Citric acid 0.15 Citric Acid Trisodic citrate 1.20 Sodium Citrate Part B Cremophor RH60 ™ 3.00 PEG-60 Hydronegated Ingredient according to the 2.00 Castor Oil invention Part C Texapon NSO UP ™ 20.00 Sodium Laureth Sulfate Crodateric CAB-30 5.00 Cocamidopropyl Betaine LQ-(MH) ™ Phenoxyethanol qs Phenoxyethanol Perfume 0.10 Fragrance Crothix Liquid LQ-(RB) ™ 3.00 PEG-150 Pentaerythrityl Tetrastearate & PEG-6 Caprylic/Capric Glycerides & Aqua

(117) Protocol: Weigh part A and heat at 75° C. in a water bath. Mix well. Weigh part B and heat at 75° C. in a water bath. Mix well. Add part B to part A under stirring. Add the ingredients of part C, one by one, in the previous part under stirring. Mix well.

(118) Examples of Active Ingredient, Marketed by Sederma, that can be Added to this Formulation: CERAMIDE A2 PH™: chemical analogue of ceramide 2, a naturally occurring molecule of the hair. Acting by strengthening the hair structure, protecting and sheathing damaged hair, including colored or permed hair. CAPIGENE SP™: ingredient comprising three complementary actives: homotaurine, a bacterial filtrate rich in peptides and sulfomucopolysaccharides extract of marine origin. Acts by slowing hair loss, stimulating the renewal and regeneration of hair and involved in the regulation of seborrhea often implicated in alopecia phenomena. Contributes to the health and strength of the scalp and hair. HELIOGENOL™: hydro glycolic extract of sunflower seeds titrated in polyphenols. Naturally comprises a free radical captor. Protects and repairs the natural and colored hair against the aggression of shampoos and UV rays. CAPILECTINE SP™: glycoprotein with a molecular weight of about 20,000 daltons, purified from Solanum tuberosum L. which has similar characteristics to those of lectins. Stimulates hair vitality.

(119) 1.2 «Leave on»

(120) TABLE-US-00012 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Citric acid 0.15 Citric Acid Trisodic citrate 1.20 Sodium Citrate Potassium sorbate Qs Potassium Sorbate Keltrol CG-SFT ™ 0.30 Xanthan Gum Part B Cremophor RH60 ™ 0.40 PEG-60 Hydronegated Ingredient according 3.00 Castor Oil to the invention Part C Ethanol 96° 5.00 Glycerin Phenoxyethanol qs Phenoxyethanol Perfume 0.10 Fragrance Part D Incroquat CTC-30 1.00 Cetrimonium Chloride LQ-(MH) ™

(121) Protocol: Sprinkle xanthan gum under rapid stirring into part A and let rise for 30 minutes. Heat part A at 75° C. in a water bath. Weigh part B and heat at 75° C. in a water bath. Mix well. Add part C, below 35° C., mix well. Add part C in the previous part under stirring; mix well. Add part D slowly. Mix well.

(122) Examples of active ingredient, marketed by Sederma, that can be added to this formulation: as previously for the shampoo, and/or PACIFEEL™: active ingredient actif marketed by Sederma, comprising a natural extract of the Mirabilis Jalapa plant also known as the Marvel of Peru, which alleviates cutaneous discomfort, fades redness of sensitive and reactive skin and strengthens and hydrates the epidermis.

(123) 1.3 Tonic Emulsion

(124) TABLE-US-00013 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Citric acid 0.15 Citric Acid Trisodic citrate 1.20 Sodium Citrate Potassium sorbate qs Potassium Sorbate Part B Butylen glycol 2.00 Butylen Glycol Keltrol CG-SFT ™ 0.30 Xanthan Gum Part C Cremophor RH60 ™ 3.50 PEG-60 Hydronegated Ingredient according 3.00 Castor Oil to the invention Part D Phenoxyethanol qs Phenoxyethanol Perfume 0.10 Fragrance Part E Incroquat CTC-30 2.00 Cetrimonium Chloride LQ-(MH) ™

(125) Protocol: Weigh part A. Mix under stirring. Weigh part B and homogenize. Add part B to part A under stirring. Let rise for 30 minutes. Heat part A+B at 55° C. in a water bath. Weigh part C and heat at 55° C. in a water bath. Add part C into part A+B under rapid stirring. Add part E in the previous part under gentle agitation. Mix well.

(126) An opaque fluid emulsion is obtained.

(127) Examples of Active Ingredient, Marketed by Sederma, that can be Added to this Formulation: PROCAPIL™: anti-hair-loss active ingredient marketed by Sederma (WO00/58347) that combines a vitamin matrikine (biotinyl-GHK), apigenin (a flavonoid extracted from citrus) and oleanolic acid (root extract from Loveyly Hemsleya).

(128) 1.4 Smoothing Serum (Cream Emulsion)

(129) TABLE-US-00014 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Optasense G83 ™ 0.20 Carbomer Part B Zémea ™ 5.00 Propanediol Phenoxyethanol qs Phenoxyethanol Part C Ingredient according 3.00 Acrylates/C10-30 Alkyl to the invention Acrylate Crosspolymer Pemulen TR-2 ™ 0.20 Part D Potassium sorbate qs Potassium Sorbate Part E H.sub.2O 3.00 Water NaOH 30% 0.30 Sodium Hydroxyde Part F Ethanol 96 surfin 8.00 Perfume 0.10

(130) Protocol: Part A: sprinkle carbomer in water. Let swell 30 minutes. Weigh part B and mix. Add part B and mix. Add part B to part A under normal agitation. Weigh part C and mix. Add part C to part A+B. Homogenize under stronger stirring. Weigh part D. Extemporaneously pour part D into part A+B+C under stirring. Neutralize with part E to pH=5.60+/−0.10 under normal agitation. Weigh part F and stir. Add part F in the previous part under normal agitation.

(131) 1.5 Mask

(132) TABLE-US-00015 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Potassium sorbate qs Potassium Sorbate Part B Rejuvasoft-PA-MH ™ 6.00 Polyquaternium-91 & Cetearyl Terraquat BD-PA-MH ™ 1.00 Alcohol & behentrimonium Crodacol CS90-PA-(RB) ™ 2.00 Chloride & Myristyl Myristate Ingredient according to the 3.00 Bis-(Ethyl PPG-3 Behenate) invention Dimonium Methosulfate & Behenamidopropyl Dimethylamine Cetearyl Alcohol Part C Glycerin 3.00 Glycerin Phenoxyethanol qs Phenoxyethanol Part D Perfume 0.10 Fragrance

(133) Protocol: Weigh part A. Heat at 85° C. in a water bath. Weigh part B and heat at 85° C. in a water bath. Weigh part C and homogenize. Add part C to part A under stirring. Add part B to part A+C under rapid stirring for 30 s. Add part D at 35° C. under stirring.

(134) An opaque viscous cream is obtained.

(135) Examples of Active Ingredient, Marketed by Sederma, that can be Added to this Formulation: HAIRSPA™: Scalp moisturisation and soothing active ingredient comprising lactitol and xylitol in glycerin, acts on skin microflore balance to fight against scalp discomfort (dryness, itching, dandruff, irritations). FRUITBIO™: Complex of α-hydroxy acids associated with green tea extract. Smoothing hair cuticle.

(136) 1.6 Oil

(137) TABLE-US-00016 PRODUCT % INCI NAME Part A BRB CM 56 ™ Qsp100 Cyclopentasiloxane & Cyclohexasiloxane XIAMETER PMX 200 5cs ™ 6.00 Dimethicone BRB PTM 20 ™ 2.00 Phenyltrimethicone Crodamol DA-LQ-(RB) ™ 10.00 Diisopropyl Adipate Arlamol HD-LQ-(RB) ™ 5.00 Isohexadecane Crodamol TN-[EU]-LQ-(JP) ™ 5.00 Isotridecyl isononanoate Ingredient according to the 3.00 invention Part B Phenoxyethanol qs Phenoxyethanol Perfume 0.20 Fragrance Ethanol 96° 5.00 Alcohol

(138) Protocol: Weigh part A and put under gentle stirring. Weigh part B and homogenize. Add part B into part A under gentle stirring. Mix well.

(139) A colorless clear oil is obtained.

(140) 1.7 Cleansing Conditioner

(141) TABLE-US-00017 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Potassium sorbate Qs Potassium Sorbate Incromide Oxide 2.00 Cocamidopropylamine Oxide C-LQ-(MH) ™ & Water Lustreplex-LQ-(MH) ™ 1.50 Polyquaternium-70 & Dipropylene Glycol Part B Crodazoquat 1.50 Behentrimonium Methosulfate MCC-PA-MH ™ & Cetearyl Alcohol & Crodacol CS-PA-(RB) ™ 3.00 Quaternium-86 Ingredient according to the 2.00 Cetearyl Alcohol invention Part C Glycerin 3.00 Glycerin Crovol A70-LQ-(RB) ™ 1.00 PEG-60 Almond Glycerides Phenoxyethanol qs Phenoxyethanol Part D Perfume 0.10 Fragrance

(142) Protocol: Weigh part A and heat in a water bath at 85° C. Weigh part B and heat in a water bath at 85° C. Weigh part C and homogenize. Add part C to part A under normal agitation. Add part B to part A+C under rapid stirring. Add part D at 35° C. under stirring and mix well.

(143) Example of Active Ingredient, Marketed by Sederma, that can be Added to this Formulation:

(144) CERAMIDE A2 PH™

(145) 1.8 Biphasic Spray

(146) TABLE-US-00018 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Potassium sorbate qs Potassium Sorbate Part B Crovol A70-LQ-(RB) ™ 1.00 PEG-60 Almond Glycerides Phenoxyethanol qs Phenoxyethanol Part C Crodamol DA-LQ-(RB) ™ 24.00 Diisopropyl Adipate Crodamol TN-[EU]- 3.00 Isotridecyl Isononanoate LQ-(JP) ™ Ingredient according to the 3.00 invention Perfume 0.20 Fragrance

(147) Protocol: Weigh part A and mix under slow stirring. Weigh part B and homogenize. Add part B to part A. Mix well under rapid stirring. Weigh part C and homogenize. Add part C into part A+B under stirring.

(148) Example of Active Ingredient, Marketed by Sederma, that can be Added to this Formulation: FRUIT BIO™

(149) 2) Skin Treatment

(150) Face Cream for Oily Skin and/or Antiaging

(151) TABLE-US-00019 PRODUCT % INCI NAME Part A H.sub.2O Qsp100 Water Carbopol Ultrez 10 0.25 Carbomer Part B Glycerin 3.50 Glycerin Part C Brij S2 SS 0.40 Steareth-2 Brij S10 SO 1.20 Steareth-10 Crodafos CES 4.00 Cetearyl Alcohol & Dicetyl Vaseline oil 2.50 Phosphate & Ceteth-10 Xiameter PMX-0345 2.00 Phosphate Crodamol OSU 7.00 Mineral Oil Preservative qs Cyclopentasiloxane & Cyclohexasiloxane Diethylhexyl Succinate — Part D Ingredient according 3.00 to the invention Part E Potassium sorbate 0.10 Potassium Sorbate Part F H.sub.2O 4.00 Water NaOH 30% 0.40 Sodium Hydroxide Part G Perfume 0.10 Fragrance

(152) Protocol: Part A: Sprinkle Carbomer in water and let swell for 1 hour without stirring. Weigh and add part B into part A. Homogenize. Heat part A+B in a water bath at 75° C. Weigh and heat part C in a water bath at 75° C. Mix well. Weigh part D. Add part D into part C, homogenize. Add part C+D in part A+B under stirring. Extemporaneously, add part E in the emulsion under stirring. Add part F in the emulsion. Cool under stirring. Adjust pH to 5.90+−0.10 using part F, below 35° C. Add part G, mix well.

(153) Examples of Active Ingredient, Marketed by Sederma, that can be Added to this Formulation: MATRIXYL™3000: peptide-based anti-wrinkle ingredient marketed by Sederma (WO2005/048968) comprising two matrikines Pal-GHK and Pal-GQPR, which in synergy helps repairing skin damages caused by aging. MATRIXYL synthe'6™: peptide-based anti-wrinkle ingredient marketed by SEDERMA which helps repair skin damage caused by aging. PACIFEEL™ Ac-Net™: an active sold by SEDERMA (WO2003/02828692) offering a complete treatment of oily and acne-prone skins. EVERMAT™: active marketed by SEDERMA (WO2007/029187), which decreases the secretion of sebum and thus participates in the treatment of oily skin.

(154) E) In Vivo Tests

(155) Principle

(156) Two separate studies were conducted on a total of 106 volunteers: Study A on a panel of 46 volunteers, mean age 38 years [21-59 years], with sensitive scalp, itching and dandruff in most cases. Study B on a panel of 60 volunteers, mean age 38 years [19-63 years], half with oily dandruff and half with dry dandruff, and itching in almost all cases.

(157) The evaluation of the efficacy of the extract according to the invention was conducted on their scalp around three major axes:

(158) 1. Improvement of dandruff states: By a dermatologist assessment, Visualization on macrophotos, A quantization by confocal laser microscopy and A self-assessment

(159) 2. The restoration of skin barrier: With a measure of the TEWL using a VapoMeter, Of Hydration using a DermaLab™ and Corneometer™ and Of sebum rate using a Sebumeter

(160) 3. The decrease of itching: With a dermatologist evaluation and A self-assessment

(161) Protocol

(162) Particular Inclusion Criteria

(163) For the 2 studies, volunteers have observed a period of “wash-out” with a neutral shampoo. Hormonal constancy during the 3 months before the test and during the test was asked to women. During the test, moderate sun exposure, the exclusive use of hair products supplied and refrain from going to the hairdresser were requested.

(164) Study Type and Duration

(165) Studies were conducted single-blind on the whole scalp. The treatment consisted in use, at least 3 times per week, for 3 weeks, a shampoo and then a non-rinsed after-shampoo lotion (or “Leave-on”) either placebo either comprising 2% respectively (shampoo) and 3% (“Leave-on”) of the ingredient comprising the extract according to the invention (according to formulas 1.1 and 1.2 given above in § D).

(166) The synopsis of the study can be summarized according to the following diagram.

(167) TABLE-US-00020 T 7 days T0 (Study B only) T 21 days Dandruff Dandruff Dandruff Dermatologist Dermatologist Dermatologist Macrophotos . . . Macrophotos Confocal microscopy . . . Confocal microscopy . . . Self-assessment Self-assessment Barrier Barrier Barrier VapoMeter ™ . . . VapoMeter ™ DermaLab ™ . . . DermaLab ™ Corneometer ™ Corneometer ™ Corneometer ™ Sebumeter ™ Sebumeter ™ Sebumeter ™ Itching Itching Itching Dermatologist Dermatologist Dermatologist . . . Self-assessment Self-assessment

(168) Statistical studies were performed using the Student's t test or, if needed, a Wilcoxon or Mann-Whitney non-parametric test. To compare the effect to T0, two-sided tests were performed on paired series. To compare two products, two-sided tests were performed on non-paired series. A Chi2 test was used for the questionnaire evaluation.

(169) Results

(170) 1) Evaluation of Dandruff

(171) a) Clinical Evaluation by a Dermatologist (Study B)

(172) At each interval, a dermatologist assessed the number and size of the dandruff according to the following table:

(173) TABLE-US-00021 7 Numerous and large 6 Numerous and small 5 Large 4 Small 3 Few and large 2 Few and smal 1 None

(174) These results show that using the treatment with the products of the invention leads to a clear reduction in dry and oily dandruff compared to T0 and compared to the placebo. After 3 weeks, the scores are improved by 61% (dry dandruff, p<0.01 vs. placebo) and 64% (oily dandruff, p<0.05 vs. placebo). Scalp condition became almost normal with few small scales (scores of 2.0 and 1.9).

(175) Using the placebo treatment did not lead to a significant reduction in dry dandruff (score decreasing from 5.0 to 4.2) and, in the oily dandruff, to a lesser score reduction score (from 5.1 to 3.9 p<0.01) than obtained with the products of the invention.

(176) Advantageously, efficacy was noted after just 7 days on both types of dandruff, with −31% for oily dandruff (p<0.01 vs. T0) and −20% for dry dandruff (p<0.05 vs. T0).

(177) b) Self-Evaluation by Volunteers (Study B)

(178) At the same time, the volunteers assessed the effects of the treatment themselves. The results support the dermatologist's analysis.

(179) After 3 weeks of application:

(180) Whether for the dry or oily dandruff, 93% of the volunteers applying the treatment with the products of the invention saw a significant improvement in their condition (less dandruff) compared to T0 (p<0.01). These values are also significant compared to the placebo (p<0.01 and p<0.05).

(181) They are far fewer to see an improvement with the placebo (40% for dry and 53% for oily skin; not significant in 2 cases).

(182) A much higher proportion (73 to 80%) even saw their dandruff disappear following the treatment with the products of the invention. The difference with the panel having applied a placebo is very clear, significant (p<0.05).

(183) c) Evaluation on Macrophotos (Study A) Dandruff was visualized and evaluated by eight experts on standard photos taken using a dermoscopic camera, VivaCam® (Mavig GmbH VivaScope Systems, Germany). Each image contains 1600×1200 pixels for a 9×7 mm measurement field.

(184) The photos of the volunteers showing clearly visible and sufficient dandruff at T0 were selected for the analysis, therefore a total of 17 volunteers for the product and 17 volunteers for the placebo (around 70% of the panel). The photos taken after 3 weeks were compared to those from T0 and the experts were to respond to the following assertion: “the scalp shows less scale after treatment”.

(185) In the panel having used the products according to the invention, 68% of responses point towards a reduction in scales was noted. The 68% response rate is significantly different from all non-positive responses (8% Do not agree+24% Neither agree nor disagree). Furthermore, a significant difference compared to the placebo panel was noted on which only 35% of responses are in favor of an improvement in dandruff, the undecided being almost twice as many than for the panel having applied the products of the invention (46% vs. 24%).

(186) d) Evaluation by Confocal Microscopy (Study A)

(187) It is commonly accepted that subjects with confirmed dandruff have a hyperproliferative epidermis and a thicker albeit imperfect stratum corneum. In order to assess the effect of the products of the invention on this parameter, the thickness of the stratum using a confocal laser microscope (VivaScope® 3000; Mavig GmbH, Germany) was measured.

(188) The laser light emitted by this device in the skin is reflected differently according to the structures with which it comes into contact (keratin, melanin, collagen). A specific optical system is used to reconstitute a clear image of these structures at a chosen depth. Horizontal optical sections of the epidermis and dermis, a few microns apart in depth, are thus obtained.

(189) During this study, images were acquired at different depths at 2.6 μm intervals in order to reproduce the entire epidermis and the stratum corneum in particular.

(190) TABLE-US-00022 TABLE 10 Evaluation of the thickness of the stratum corneum on the scalp after 3 weeks of application of the products according to the invention (n = 23) or placebos (n = 22) Products of the invention Placebos T0 T 3 weeks T0 T 3 weeks Mean (μm) +/− 20.3 +/− 17.6 +/− 19.7 +/− 21.3 +/− Sd 5.8 4.4 4.8 5.0 % variation vs. −13.3%   8.1% T0 Significance p < 0.01 p < 0.05 vs. T0 Maximum −47% Responders   70% Significance p < 0.01 vs. placebos

(191) Analysis of the results shows an increase of 8.1% (p<0.05) of the stratum corneum thickness after 3 weeks use of the placebos. In parallel the use of the product of the invention causes a significant 13.3% decrease in stratum corneum thickness. This reduction is also significantly different from that which is observed for the placebo (p<0.01). This data would appear to indicate an improvement in stratum corneum quality thanks to the product of the invention, and the TEWL and hydration results below confirm this.

(192) 2) Evaluation of the Cutaneous Barrier

(193) It is known that the quality of the cutaneous barrier of the scalp is related in particular to a good transepidermal water loss value (or TEWL) and a good hydration.

(194) TEWL measurement was conducted in study A. Two hydration measurements were conducted respectively on the panel of study A and on the panel on dry dandruff of study B.

(195) a) TEWL Measurement by the VapoMeter™ (Study A)

(196) Plastic stencils and anatomical landmarks were used to mark out the specific areas on the scalp. TEWL was measured nine times (3 per site×3 sites) using the VapoMeter™ (Delfin Technologies, Finland) on the same sites at T0 and after T3 weeks.

(197) TABLE-US-00023 TABLE 11 Evaluation of the average TEWL on the scalp after 3 weeks of application of the products according to the invention (n = 20) or placebos (n = 22) Products of the invention Placebos T0 T3 weeks T0 T3 weeks Mean 18.9 +/− 17.6 +/− 19.9 +/− 20.8 +/− (g/m.sup.2/h) +/− 4.2 3.8 4.7 2.8 Sd % variation vs. −6.9% +4.5% T0 Significance p < 0.07 nsd vs. T0 Maximum  −36% Responders   65% Significance p < 0.05 vs. placebos nds: non significant difference

(198) These results show that the mean TEWL value is non-significantly increased by +4.5% following use of the placebos. At the same time, on the panel having used the products of the invention for 3 weeks, a 6.9% decrease in mean TEWL is noted, significant at p<0.07 vs. T0 and significant at p<0.05 vs. placebos. This data therefore shows the beneficial and restructuring effect of the products according to the invention on the scalp skin barrier.

(199) b) Evaluation of the Scalp Hydration (Study A and B)

(200) Scalp hydration was measured by impedance measurement using a Corneometer® (C&K, Germany) for the dry dandruff panel of study B and using a DermaLab® with pin probe (Cortex, Denmark) for the complete panel of study B. The DermaLab® is especially suitable for measuring scalp hydration due to the structure of its eight-pin probe with 6 mm pins for easy access to the scalp and which prevents water collection on the probe.

(201) Measurements on the Corneometer® were carried out three times on the hair line whereas the DermaLab® measurements were carried out three times on two separate sites on the scalp.

(202) TABLE-US-00024 TABLE 12 Evaluation of the hydration of the scalp after 1 and 3 weeks of application of the products according to the invention or placebos. Corneometer Dermalab Products according Products according Placebos to the invention Placebos to the invention T0 T1s. T3s. T0 T1s T3s. T0 T3s. T0 T3s. Mean 34.3 33.6 34.2 32.3 34.3 35.1 59.8 54.9 56.5 63.3 +/−Sd 1.8 1.8 2.0 2.3  2.4  2.4 23.9 24.4 26.8 19.6 % variation vs. T0 −2% −0.3% +6.2%  +8.7%  −8.2% +12% Significance vs. T0 nds nds p < 0.01 p < 0.01 nds p < 0.05 Maximum  18%  19% 148% Responders 100% 100%  73% Significance vs. p < 0.01 p < 0.01 — p < 0.05 placebos Corneometer n = 15 for the 2 cases; Dermalab: n = 20 for the products according to the invention, n = 22 for the placebos

(203) These results, from two different panels, of which one specifically dry, in two separate studies and using two methods, show that application of the products of the invention increases scalp hydration. On a dry scalp, from 7 days an increase of +6.2% (p<0.01 vs. placebo) and an increase of +8.7% at T3 weeks (p<0.01 vs. placebo) are observed. With the pin probe method, the results show a 12.1% increase (p<0.05 vs. placebo). These results are highly complementary, the difference possibly attributable to the panel, method or the probe.

(204) 3) Evaluation of the Sebum Level

(205) As scalp sebum level is a key criterion in the appearance of dandruff. This parameter is also centrally in the profile of an oily skin. It was monitored on the oily dandruff panel of study B using the Sebumeter® (C&K, Germany) which directly measures sebaceous secretion by photometry. The Sebumeter® probe comprises a mirror on which an opaque film is placed and which becomes more or less transparent depending on the sebum adsorbed by it after repeated application to the skin. A photoelectric cell analyses film transparency making it possible to deduce the sebum level. The oily dandruff panel was used for this study.

(206) TABLE-US-00025 TABLE 13 Evaluation of sebum content on the scalp after 1 and 3 weeks of application of the products according to the invention (n = 15) or placebos (n = 15). Products of the invention Placebos T1 T3 T1 T3 T0 week weeks T0 week weeks Mean (μg 182.1 132.5 119.6 166.5 157.8 157.5 sébum/cm.sup.2) +/−Sd +/−12.5 +/−8.3 +/−8.8 +/−8.6 +/−9.7 +/−10.2 % variation — −27.2%.sup.  −34.3%.sup.  — −5.2% −5.4% vs. T0 Significance p < 0.01 p < 0.01 nds nds vs. T0 Maximum −47% −61% Responders  93% 100% Significance p < 0.01 p < 0.01 vs. placebos

(207) The applying of the products of the invention provides a very clear reduction in sebum level of −27%, as from the first week, which is amplified after 3 weeks to reach −34%. These decreases are highly significant compared to T0 (p<0.01) and compared to the placebos (p<0.01). The condition of the scalp in the subjects with oily dandruff was clearly improved.

(208) 4) Itching

(209) a) Itching Evaluation by Dermatologist and Self-Evaluation (Study B)

(210) 44% of the French population declares to have a sensitive scalp, and besides it is shown that dandruff leads to a prevalence of itching and irritation that is three times higher.

(211) After 1 and 3 weeks use of the products of the invention by the dry and oily dandruff panels, a dermatologist assessed the frequency and intensity of itching on the basis of the volunteers' declarations and according to the following table:

(212) TABLE-US-00026 Itching score-Frequency Itching score-Intensity 1 None None 2 Mild (few episodes per day) Mild 3 Moderate (some episodes per day) Moderate 4 Remarkable (numerous and frequent Patent daily episodes)

(213) This study shows that seven days after application of the products of the invention, a reduction in itching, as much on dry or oily scalp, was observed (around −15%, p<0.05). This reduction was amplified to reach −40% (p<0.01 vs. T0 and p<0.05 vs. placebo) after 21 days of treatment. The sensation scores after 21 days of application corresponded practically to no itching. At the same time, application of the placebos provided almost no changes. This analysis applies to both the frequency and the intensity of itching.

(214) At the same time, volunteers also assessed themselves the reduction in irritation and itching and the calming effect of the treatments. The results support the dermatologist's analysis.

(215) In both panels, 100% of volunteers experienced less itching after using the products of the invention, with a much lower percentage after using the placebos (66%). The variation compared to the placebos is significant at p<0.05 for both panels. For irritation, the results were also in favor of the products of the invention with 93% (oily dandruff panel) and 100% (dry dandruff panel) decrease compared to just 80% and 60% for the placebos.

(216) Finally, the volunteers mainly agreed on a lasting calming effect after application of the product of the invention (80% and 93%) whereas the placebo only induced this effect on a smaller percentage at 53% in both panels. For the dry dandruff panel, this variation is significant with regard to the placebo panel at p<0.05.

(217) b) Histamine on Scalp

(218) In addition to the results on the feelings of the volunteers, histamine in the scales has been evaluated.

(219) Histamine is an immune system signaling molecule also found in the skin where it acts on certain receptors and causes pruritus (skin itching). Histamine levels two times higher were observed on the scalp of subjects with dandruff, these quantities clearly reducing following an effective anti-dandruff treatment. The decrease of the level of this substance makes it possible to predict and monitor scalp soothing.

(220) To test the histamine levels, adhesive strips to take samples of scales from subjects with dandruff were used. These samples, which were reproducible, were taken from a line running from the forehead to the vortex, marked according to anatomical landmarks and stencils between T0 and T3 weeks. Once loaded with scales, the adhesive tapes were extracted in a buffer and histamine levels tested using an ELISA kit. At the same time, the BCA method was used to test protein levels in order to normalize the results.

(221) 43 samples were taken (3 could not be tested) from 20 people having applied the placebo treatment (shampoo+leave-on lotion) for 21 days, and from 23 others having used the treatment with the products of the invention (shampoo at 2%+leave-on lotion at 3% of the ingredient comprising the extract according to the invention) with the formulas 1.1 and 1.2 given in the galenic part above.

(222) TABLE-US-00027 TABLE 14 Modulating the amount of histamine in dander, effect of the products according to the invention or placebos. T0; T3 weeks; Variation Histamine Histamine vs. (nM/mg (nM/mg Variation placebos protein) protein) vs. T0 (%) (%) Placebos 7213 +/− 6311 +/− −13%; — 5926 7146 nds Products of 7485 +/− 4026 +/− −46%; −33%; the invention 9596 4723 p < 0.01 p < 0.05

(223) The results above show that using the scalp treatment with the products of the invention provides a reduction of the amount of histamine found in the scales. The decrease is important (−46% compared to T0 and significant at p<0.01) and significant compared to the placebos (−33%, p<0.05). The reduction of this agent, known to cause itching, confirms the self-evaluation and the dermatologist's data.